



Supporting Information

for

Nanostructured lipid carriers containing benzimidazole: physicochemical, biopharmaceutical and cellular in vitro studies

Giuliana Muraca, María Esperanza Ruiz, Rocío C. Gambaro, Sebastián Scioli-Montoto, María Laura Sbaraglini, Gisel Padula, José Sebastián Cisneros, Cecilia Yamil Chain, Vera A. Álvarez, Cristián Huck-Iriart, Guillermo R. Castro, María Belén Piñero, Matias Ildebrando Marchetto, Catalina Alba Soto, Germán A. Islan and Alan Talevi

Beilstein J. Nanotechnol. **2023**, *14*, 804–818. [doi:10.3762/bjnano.14.66](https://doi.org/10.3762/bjnano.14.66)

Supplementary material

Table S1: Goodness-of-fit measures of mathematical models of drug release for NLC-BNZ.

Model	R^2	R^2 -adjusted	MSE	AIC
First order	0.97	0.97	14	22
Hopfenberg	0.95	0.94	37	27
Baker–Lonsdale	0.90	0.90	57	29
Korsmeyer–Peppas	0.99	0.99	5	18
Hixon–Crowell	0.95	0.95	27	25




Figure S1: Dose-response effect of myristyl myristate on *T. cruzi* amastigotes.




Figure S2: Flow cytometry measurements of cell cytotoxicity in Vero cells treated with free BNZ, NLC-VEHICLE, and NLC-BNZ.